

Prolia and Xgeva - (60mg/mL, 70mg/mL; Injection, Subcutaneous)

Generic Name	Denosumab	Innovator	Amgen
Dosage	60mg/mL, 70mg/mL; Injection, Subcutaneous	Branded US Sales	More Than \$1000 mn
Probable FTF	None	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	Prolia is a RANK ligand (RANKL) inhibitor indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Xgeva is a RANK ligand (RANKL) inhibitor indicated for Prevention of skeletal-related events in patients with bone metastases from solid tumors		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.